Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Alisertib + Irinotecan + Temozolomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Alisertib||MLN8237||Aurka Inhibitors 23||Alisertib (MLN8237) binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation (PMID: 26999067, PMID: 32414750).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 8||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Temozolomide||Temodar||Methazolastone||Chemotherapy - Alkylating 14||Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||neuroblastoma||not applicable||Alisertib + Irinotecan + Temozolomide||Phase I||Actionable||In a Phase I trial, the combination of Alisertib (MLN8237), Camptosar (irinotecan), and Temodar (temozolomide) demonstrated safety and preliminary efficacy in neuroblastoma patients, resulting in an overall response rate of 31.8% and a 2-year progression-free survival rate of 52.4% (PMID: 26884555).||26884555|
|Unknown unknown||neuroblastoma||not applicable||Alisertib + Irinotecan + Temozolomide||Phase II||Actionable||In a Phase II trial, the combination of Alisertib (MLN8237), Camptosar (irinotecan), and Temodar (temozolomide) resulted in a response rate of 21.1% (4/19) in patients with neuroblastoma, with 4 partial responses, 2 minor responses, and 5 stable diseases (PMID: 30093449; NCT01601535).||30093449|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01601535||Phase Ib/II||Alisertib + Irinotecan + Temozolomide||Study of MLN8237 in Combination With Irinotecan and Temozolomide||Completed|